CTRI/2023/03/050180招募中3 期
DAHLIA: Docetaxel with Abiraterone full versus low dose in Hormone SensitiveAdvanced Prostate Cancer â?? Phase III, Non-Inferiority Randomized Control OpenLabel Trial. - DAHLIA
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •participants must be hormone sensitive prostrate cancer.
- •Age above 18 years
- •ECOG permance status <2
- •participants must have normal organ and marrow function
排除标准
- •1.participants who are receiving any other investigational agents.
- •2.participants who are designated as unfit for receiving Abiraterone
研究者
相似试验
招募中
2 期
pfront therapy in high risk metastatic prostate cancermetastatic hormone naive prostate cancerprostate cancer, hormone naive, metastaticJPRN-jRCTs021180021arita Shintaro100
尚未招募
2 期
To study whether maintenance treatment with Abiraterone after docetaxel chemotherapy leads to further improvement in metastatic hormone sensitive prostate cancer.CTRI/2020/02/023447Tata Memorial Centre
尚未招募
2 期
Docetaxel versus Docetaxel and Lapatinib in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) An open label multicenter randomized phase II study. A study of the Dutch Head and Neck Cancer Group (DHNCG) (NWHHT 08-02)SCCHN10027476NL-OMON32481Antoni van Leeuwenhoek Ziekenhuis74
招募中
不适用
Docetaxel versus Docetaxel and Lapatinib in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). An open label multicenter randomized phase II study.A study of the Dutch Head and Neck Cancer Group (DHNCG)(NWHHT 08-02).patients with recurrent SCCHN not amendable for local therapy or patients with metastatic SCCHNKeywords: SCCHN, recurrent and/or metastatic disease, docetaxel, lapatinibNL-OMON22962The Netherlands Cancer Institute Antoni van Leeuwenhoek hospitalDutch Head and Neck Cancer Group (DHNCG)74
招募中
3 期
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)10038597prostate cancerNL-OMON54758Memorial Sloan Kettering Cancer Center250